FABP4 and hepatocellular carcinoma: For example, FABP4 enhances mitochondrial β-oxidation to reduce cisplatin-induced apoptosis in ovarian cancer[73], while FABP5 promotes chemoresistance in hepatocellular carcinoma through the HIF-1α pathway[96], and FABP6 enhances CRC resistance to oxaliplatin through KLF5-dependent transcription[131].